NKTX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.303

-13.33%

-0.313

-27.13%

-0.320

+3.23%

Estimates Revision

Stock Price

Go Down

-5.64%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast NKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NKTX is 12.33 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 1.840

Low

10.00

Averages

12.33

High

16.00

Current: 1.840

Low

10.00

Averages

12.33

High

16.00

Stifel

Buy

downgrade

$12 -> $11

2025-11-11

Reason

Stifel

Price Target

$12 -> $11

2025-11-11

downgrade

Buy

Reason

Stifel lowered the firm's price target on Nkarta to $11 from $12 and keeps a Buy rating on the shares. The firm believes management's decision to forego a preliminary year-end 2025 data disclosure and instead guide to the presentation of a more-fulsome data set at a FY26 medical conference should remove a near-term overhang given the former disclosure format was perceived to be mostly inconclusive, the analyst tells investors following the Q3 update.

Stifel

Stephen Willey

Buy

downgrade

$14 -> $12

2025-08-14

Reason

Stifel

Stephen Willey

Price Target

$14 -> $12

2025-08-14

downgrade

Buy

Reason

Stifel analyst Stephen Willey lowered the firm's price target on Nkarta to $12 from $14 and keeps a Buy rating on the shares. The recent earnings announcement and corporate update did not provide "any incremental surprises" as management is still guiding to the disclosure of preliminary data from the Ntrust-1/2 trials evaluating NKX019 in autoimmune disease before year-end, the analyst tells investors. The firm's reduced price target mostly reflects revised longer-term financing assumptions and valuation, the analyst noted.

Mizuho

Outperform -> NULL

downgrade

$16 -> $14

2025-06-10

Reason

Mizuho

Price Target

$16 -> $14

2025-06-10

downgrade

Outperform -> NULL

Reason

Mizuho lowered the firm's price target on Nkarta to $14 from $16 and keeps an Outperform rating on the shares. The firm updated the company's model post the Q1 report. It moderated the near-term ramp and unadjusted peak sales for NKX019, citing the current competitive landscape in autoimmune diseases.

William Blair

Outperform -> Market Perform

downgrade

2025-05-15

Reason

William Blair

Price Target

2025-05-15

downgrade

Outperform -> Market Perform

Reason

Needham

Gil Blum

Strong Buy

Reiterates

$11

2025-04-09

Reason

Needham

Gil Blum

Price Target

$11

2025-04-09

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

$18

2025-03-27

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$18

2025-03-27

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Nkarta Inc (NKTX.O) is -1.45, compared to its 5-year average forward P/E of -4.82. For a more detailed relative valuation and DCF analysis to assess Nkarta Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.82

Current PE

-1.45

Overvalued PE

0.18

Undervalued PE

-9.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.47

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.86

Undervalued EV/EBITDA

-4.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NKTX News & Events

Events Timeline

No data

News

1.0

12-02Globenewswire

Nkarta (NKTX) Participates in Evercore 8th Annual Healthcare Conference to Showcase NK Cell Therapy Progress

1.0

10-30Newsfilter

Nkarta to Attend Investor Conferences in November

1.0

10-22Newsfilter

Nkarta to Present Poster at the Upcoming American College of Rheumatology (ACR) Convergence Meeting

People Also Watch

Frequently Asked Questions

What is Nkarta Inc (NKTX) stock price today?

The current price of NKTX is 1.84 USD — it has decreased -2.13 % in the last trading day.

What is Nkarta Inc (NKTX)'s business?

Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.

What is the price predicton of NKTX Stock?

What is Nkarta Inc (NKTX)'s revenue for the last quarter?

Nkarta Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Nkarta Inc (NKTX)'s earnings per share (EPS) for the last quarter?

Nkarta Inc. EPS for the last quarter amounts to -0.29 USD, decreased -25.64 % YoY.

What changes have occurred in the market's expectations for Nkarta Inc (NKTX)'s fundamentals?

The market is revising No Change the revenue expectations for NKTX for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -5.64%.

How many employees does Nkarta Inc (NKTX). have?

Nkarta Inc (NKTX) has 157 emplpoyees as of December 16 2025.

What is Nkarta Inc (NKTX) market cap?

Today NKTX has the market capitalization of 130.69M USD.